A Phase 3 interventional study of AbobotulinumtoxinA and Placebo in Glabellar Frown Lines, sponsored by Galderma R&D. Completed at 11 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-26.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
An interventional phase 3 study to evaluate efficacy and safety of a new dilution and injection volume of AbobotulinumtoxinA treatment for glabellar lines
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AbobotulinumtoxinA
Biological: AbobotulinumtoxinA
Other: Placebo
Treatment of glabellar facial lines with 50 U AbobotulinumtoxinA
Treatment of glabellar facial lines with placebo
Evaluate Composite Responder Rate at Month 1 for a Single Dose of AbobotulinumtoxinA Compared to Placebo
Composite responder is defined as a subject who achieves a score of 0 or 1 and at least 2 grades improvement on both the Investigator Live Assessment (ILA) and the Subject Self Assessment (SSA)
Time frame: Month 1 after treatment
| Milestone | Experimental | Placebo |
|---|---|---|
| Started | 224 | 77 |
| Completed | 216 | 71 |
| Not completed | 8 | 6 |
Composite responder is defined as a subject who achieves a score of 0 or 1 and at least 2 grades improvement on both the Investigator Live Assessment (ILA) and the Subject Self Assessment (SSA)
| Participants | Experimental | Placebo |
|---|---|---|
| Evaluate Composite Responder Rate at Month 1 for a Single Dose of AbobotulinumtoxinA Compared to Placebo | 142 | 0 |
Collected over 24 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Experimental | 0/223 (0%) | 4/223 (1.8%) | 24/223 (10.8%) |
| Placebo | 0/77 (0%) | 0/77 (0%) | 6/77 (7.8%) |
| Event | Experimental | Placebo |
|---|---|---|
| Worsening knee painMusculoskeletal and connective tissue disorders | 1/223 | 0/77 |
| Acute diverticulitisInfections and infestations | 1/223 | 0/77 |
| Long QT syndromeCardiac disorders | 1/223 | 0/77 |
| Worsening of hemorrhoidsGastrointestinal disorders | 1/223 | 0/77 |
| Event | Experimental | Placebo |
|---|---|---|
| HeadacheNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 19/223 | 3/77 |
| injection site painGeneral disorders | 1/223 | 2/77 |
| Eyelid ptosisEye disorders | 3/223 | 0/77 |
| Injection site discomfortGeneral disorders | 0/223 | 1/77 |
| sinus painRespiratory, thoracic and mediastinal disorders | 0/223 | 1/77 |
| MigraineNervous system disorders | 1/223 | 0/77 |
| Injection site reactionGeneral disorders | 1/223 | 0/77 |
| Age, Continuous(years) | Experimental | Placebo | Total |
|---|---|---|---|
| Mean | 44.7 ± 11.43 | 42.5 ± 11.86 | 44.1 ± 11.56 |
| Sex: Female, Male(Participants) | Experimental | Placebo | Total |
|---|---|---|---|
| Female | 195 | 69 | 264 |
| Male | 29 | 8 | 37 |
| Race (NIH/OMB)(Participants) | Experimental | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 4 | 2 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 9 | 2 | 11 |
| White | 205 | 72 | 277 |
| More than one race | 4 | 0 | 4 |
| Unknown or Not Reported | 2 | 1 | 3 |
| Region of Enrollment(participants) | Experimental | Placebo | Total |
|---|---|---|---|
| United States | 224 | 77 | 301 |
| Fitzpatrick Skin Type (FST)(Participants) | Experimental | Placebo | Total |
|---|---|---|---|
| FST I | 4 | 1 | 5 |
| FST II | 59 | 21 | 80 |
| FST III | 107 | 40 | 147 |
| FST IV | 45 | 13 | 58 |
| FST V | 3 | 1 | 4 |
| FST VI | 6 | 1 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2019 to primary completion in Sep 2019, 3 months.
Results were first posted in May 2021, 1 year 7 months after primary completion. A results delay was requested in Jul 2020.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Botulinum toxin type A